[Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene].
Selective estrogen receptor modulators (SERMs) have the potential to provide the skeletal benefits of estrogen without the increased risk of uterine and breast cancer. Raloxifene, second generation SERM has been approved for the prevention and treatment of osteoporosis. Bazedoxifene (BZA, TSE-424Z), novel SERM, acts as a tissue selective estrogen antagonist or agonist. Bazedoxifene inhibited bone turnover and prevented bone loss caused estrogen deficiency. Furthermore, this SERM did not affect the uterine endometrial thickness and reduced serum cholesterol. These date suggest that Bazedoxifene is novel potential drug for the prevention of osteoporosis in postmenopausal women.
Chaki
Osamu
O
Yokohama City University Medical Center, Section of Gynecology.
D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D019584:Hot Flashes; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D051381:Rats; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014599:Uterus / Q000187:drug effects
D007211:Indoles; D020845:Selective Estrogen Receptor Modulators; D002784:Cholesterol; C447119:bazedoxifene